Free Trial
→ Analyst nicknamed “The Prophet” issues new warning for America (From Stansberry Research) (Ad)tc pixel
NASDAQ:EOLS

Evolus Q3 2026 Earnings Date & Estimates

Evolus logo
$7.73 -0.07 (-0.90%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$7.74 +0.01 (+0.19%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Evolus is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Evolus in Q3 2026

Evolus is expected to post earnings of -$0.05 per share on revenue of $77.58 million. In the same quarter a year earlier Evolus reported -$0.14 per share on revenue of $68.97 million. Evolus last reported on May 4, 2026, posting -$0.16 per share and missing the -$0.14 consensus estimate. Evolus has beaten the consensus EPS estimate in 1 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.05
Expected Revenue
$77.58 million
Prior-Year EPS
-$0.14
Prior-Year Revenue
$68.97 million
Expected Revenue Growth
+12.5%

Recent Track Record

Last Reported
Q1 2026
Last Quarter EPS
-$0.16 (Missed by -$0.02)
Last Quarter Revenue
$73.14 million
EPS Beat Rate
1 of last 8 quarters

Prepare for the Q3 2026 Call

Evolus Q3 2026 Earnings FAQ

Evolus (NASDAQ:EOLS) is scheduled to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes.

Evolus' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Evolus to post earnings of -$0.05 per share for Q3 2026.

The consensus revenue estimate for Evolus is $77.58 million for Q3 2026.

Evolus Earnings Headlines

ARS Pharmaceuticals (NASDAQ:SPRY) vs. Evolus (NASDAQ:EOLS) Head-To-Head Comparison
October 9 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101646
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
October 8 at 10:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-evolus-inc---eols-302902096.html
First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
 |  Stansberry Research (Ad)
Reviewing Talphera (NASDAQ:TLPH) and Evolus (NASDAQ:EOLS)
October 8 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097862
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3376139/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-evolus-inc-eols.html
Evolus drops as FDA says Jeuveau Instagram post is misleading
October 2, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4649859-evolus-gets-fda-warnings-jeuveau-ig-post
See More Evolus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evolus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evolus and other key companies, straight to your email.

About Evolus

Evolus (NASDAQ:EOLS) is a commercial-stage medical aesthetics company focused on developing and marketing products for healthcare providers and consumers. The company’s portfolio is designed to address facial wrinkles, folds and other signs of aging through injectable aesthetic treatments.

Evolus’ flagship product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved in the United States for the temporary improvement of moderate to severe glabellar lines in adults. The company markets Jeuveau in the United States and sells the product internationally under the Nuceiva brand in certain markets.

The company has expanded beyond neuromodulators with its Evolysse collection of injectable hyaluronic acid dermal fillers, which is intended to address facial volume loss and wrinkles. Evolus also provides digital tools and practice-support services intended to help aesthetic providers manage patient engagement, treatment education and product purchasing.

Based in Newport Beach, California, Evolus was founded in 2012 and became a publicly traded company in 2018. David A. Moatazedi has served as the company’s president and chief executive officer since 2018. Evolus primarily serves aesthetic healthcare providers and patients in the United States, with additional international operations and distribution.

View Evolus Profile
Earnings Tools